Stories naming a tracked molecule or the drug class, linked to the original
publisher. We never reproduce article text — the quoted sentence under each fact is
shown as evidence for that fact and links back to the source.
Facts pulled from the source article, each one carrying the sentence it came from.
ResearchHealio · 2026-10-14
An analysis published in the European Heart Journal found that weight loss alone does not explain all of the cardiovascular benefits observed with semaglutide 2.4 mg in the SELECT trial.“Weight loss alone does not explain all of the cardiovascular benefits observed with semaglutide 2.4 mg in the SELECT trial, according to an analysis published in the European Heart Journal”
The researchers estimated the joint mediation of all potential risk factors combined for semaglutide's cardiovascular benefit at 31.4%.“The researchers estimated the joint mediation for all potential mediators combined as 31.4% (95% CI, 30.1% to 143.6%)”
Among individual factors analyzed, waist circumference had the largest estimated percentage of mediation, at 64%.“The estimates for percentage of mediation were largest for waist circumference (64%; 95% CI, 27.5%-179.6%)”
ResearchSTAT News · 2026-10-14
A new trial will test the real-world impacts of weekly semaglutide injections on factors like criminal justice involvement, employment, housing stability, and health care utilization.“testing the real-world impacts of weekly semaglutide injections, focusing on factors like a person’s involvement with the criminal justice system, employment, housing stability, and health c”
The trial is a collaboration between the Center for Addiction Science, Policy and Research and the Allegheny County Department of Human Services in Pennsylvania.“The trial is a collaboration between the Center for Addiction Science, Policy and Research (a nonprofit focused on GLP-1s for addiction treatment) and the Allegheny County Department of Huma”
The study is set to begin in early 2027 and will enroll up to 1,200 participants with alcohol use disorder, opioid use disorder, or both.“Set to begin in early 2027, the study will enroll up to 1,200 participants with alcohol use disorder, opioid use disorder, or both.”
MarketMedPage Today · 2026-10-13
Two deaths linked to counterfeit retatrutide were reported to the FDA.“Two recent deaths tied to counterfeit versions of retatrutide , an investigational weight-loss medication, were reported to the FDA.”
Novo Nordisk announced it will discontinue liraglutide (Saxenda) in early 2027 due to declining sales.“Novo Nordisk announced plans to discontinue its GLP-1 weight-loss injectable liraglutide (Saxenda) in early 2027 due to declining sales.”
After oral semaglutide (Wegovy) was approved for weight management, new prescriptions surpassed 100,000 within two months, according to Annals of Internal Medicine.“After the approval of oral semaglutide (Wegovy) for weight management, new prescriptions surpassed 100,000 within just 2 months.”
ResearchMedPage Today · 2026-10-13
A large retrospective cohort study found GLP-1 receptor agonists did not significantly affect anti-VEGF treatment frequency in patients with diabetic macular edema.“GLP-1 receptor agonists did not significantly affect anti-VEGF treatment frequency in patients with diabetic macular edema (DME), a large retrospective cohort study showed.”
A study found AION occurred at an average age of 62.98 among GLP-1 agonist users versus 66.45 among non-users.“AION occurred at an average age of 62.98 among GLP-1 agonist users versus 66.45 among non-users ( P <0.0001)”
An Epic Cosmos database study found an unadjusted AMD odds ratio of 1.68 among GLP-1 drug users, which changed after adjusting for certain conditions.“An unadjusted analysis produced an AMD odds ratio of 1.68 among GLP-1 drug users, including 1.53 for neovascular (n)AMD and 1.89 for dry AMD.”
InsuranceCNBC · 2026-10-13
Walmart will cover more than 250 prescriptions, including some insulin, inhalers and GLP-1s for diabetes, at no cost to employees starting in 2027.“Walmart plans to cover more than 250 prescriptions, including some insulin, inhalers and GLP-1s for diabetes, at no cost to its employees in 2027, the company confirmed to CNBC on Tuesday.”
Walmart is raising the premium for its starting health plan by $1.50 per pay period to $39.80.“raising rates for its starting plan by $1.50 per pay period to $39.80”
ResearchHealio · 2026-10-12
A Danish nested case-control study of 22,694 women aged 12-49 who used semaglutide for the first time, matched to 229,640 controls, found nine hormonal contraception regimens associated with increased odds for starting semaglutide.“nine different hormonal contraception use regimens were associated with increased odds for starting semaglutide (Ozempic/Wegovy, Novo Nordisk)”
After adjusting for BMI, the combined tablet, progestin-only tablet, and progestin-only IUD were each linked to increased odds of semaglutide initiation.“After adjusting for BMI, odds for semaglutide initiation were increased with the combined tablet (adjusted HR = 1.43; 95% CI, 1.29-1.59), progestin-only tablet (aHR = 1.52; 95% CI, 1.21-1.9)”
Researcher Mille Dybdal Bager said the study does not show a direct causal link from hormonal contraception to semaglutide initiation.“We don’t want to draw an arrow from hormonal contraception directly to semaglutide initiation, and it’s not really the interesting point in this study”
ResearchMedPage Today · 2026-10-06
A preclinical study found semaglutide (Ozempic, Wegovy) is a plausible therapy for reversing obesity-associated cardiometabolic heart failure with preserved ejection fraction (HFpEF).“Semaglutide (Ozempic, Wegovy) is a plausible therapy for reversing obesity-associated cardiometabolic heart failure with preserved ejection fraction (HFpEF), according to a preclinical study”
ResearchMedPage Today · 2026-10-06
GLP-1 medication prescribing surged from 2017 to 2025 among bariatric surgery-eligible teens, but 9 out of 10 eligible adolescents still received neither treatment, according to a JAMA Pediatrics study.“GLP-1 medication prescribing surged from 2017 to 2025 among bariatric surgery-eligible teens , yet 9 out of 10 eligible adolescents still went without either treatment.”
UTHealth Houston researchers received a $4 million NIH grant to identify genetic markers that may contribute to weight gain after stopping GLP-1 drugs.“UTHealth Houston researchers received a $4 million NIH grant to identify genetic markers that may contribute to weight gain after discontinuing GLP-1 drugs.”
The New York Times reported that people on GLP-1 medications may be reducing restaurants' revenue.“People on GLP-1 medications may be shrinking restaurants' bottom lines .”
ClinicalHealio · 2026-10-05
At 26 weeks, adults receiving semaglutide plus trevogrumab 200 mg had a 1.6 kg loss in lean mass, and those receiving semaglutide plus trevogrumab 400 mg lost 1.9 kg in lean mass compared with a 3.4 kg lean mass loss with semaglutide alone.“At 26 weeks, adults receiving semaglutide plus trevogrumab 200 mg had a 1.6 kg loss in lean mass, and those receiving semaglutide plus trevogrumab 400 mg lost 1.9 kg in lean mass compared wi”
At 1 year, adults receiving semaglutide had a 7.3% reduction in lean mass compared with a 5.8% decrease with semaglutide plus trevogrumab 25 mg and a 4.2% decline with semaglutide plus trevogrumab 75 mg.“At 1 year, adults receiving semaglutide had a 7.3% reduction in lean mass compared with a 5.8% decrease with semaglutide plus trevogrumab 25 mg and a 4.2% decline with semaglutide plus trevo”
Rosenstock said Regeneron does not plan to move forward with assessing the combination of semaglutide, trevogrumab and garetosmab-grts due to safety concerns.“Rosenstock said Regeneron does not plan to move forward with assessing the combination of semaglutide, trevogrumab and garetosmab-grts.”
Everything the feeds surfaced, newest first. Unsummarised — a reading
list rather than reporting.